Hikal Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 1,10,989 shares,. Its Average Traded Price (ATP) is ₹221.10, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 2 @ ₹222.10.
Hikal has an upper circuit limit of ₹267.78 and a lower circuit limit of ₹178.52. The total value traded stands at ₹2.45 CR, and the delivery percentage for the day is 46.93%.
The stock is currently traded with a market lot size of 1. Hikal also offers a dividend yield of 0.27%.
Hikal Share Price Chart
Hikal Share Key Metrics
Volume
1.11 L
Market Cap
2738.02 CR
LTQ@LTP
2@222.10
ATP
221.1
Var Margin
23.4 %
Circuit Range
178.52-267.78
Delivery %
46.93 %
Value
2.45 CR
ASM/GSM
No
Market Lot
1
Hikal Resistance and Support
Pivot 220.4
Resistance
First Resistance
227.75
Second Resistance
232.35
Third Resistance
239.7
Support
First Support
215.8
Second Support
208.45
Third Support
203.85
Hikal Shareholding Pattern
View More- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2024-25
- 2025-26
- 2022-23
- 2023-24
- 2026-27
Total Promoters
Hikal Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-03 | Quarterly Results |
| 2026-08-06 | Quarterly Results |
| 2026-05-27 | Audited Results & Final Dividend |
| 2026-02-11 | Quarterly Results & Interim Dividend |
| 2025-11-13 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
| 2025-08-07 | Quarterly Results |
| 2025-05-14 | Audited Results & Final Dividend |
| 2025-02-04 | Quarterly Results & Interim Dividend |
| 2024-11-12 | Quarterly Results |
| 2024-08-01 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-09-04 | 2026-09-04 | View More |
Hikal News
Hikal Ltd - 524735 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Hikal released its Q2 FY27 earnings, reporting a 36% YoY revenue growth to Rs.434 crore and a narrowed net loss of Rs.6 crore. The company also signed a multi-year CDMO contract with a European agrochemical firm and commenced commercial production at its Panoli facility.
Nov 03 2026 15:57:59
Hikal Ltd - 524735 - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026
Hikal Ltd reported its Q2 FY27 financial results with cons. revenue growing 36.3% YoY to ₹434.2 crore and net loss narrowing to ₹6.1 crore. The Pharmaceuticals segment led the revenue contribution with ₹277.8 crore, despite sales being impacted by a USFDA warning letter issued for the Jigani facility in August 2025.
Nov 03 2026 14:30:03
Hikal Ltd - 524735 - Board Meeting Intimation for Considering And Taking On Record The Standalone And Consolidated Unaudited Financial Results Of The Company.
Hikal board to meet on November 3, 2026 for financial results. The performance review covers the quarter and half-year ended September 30, 2026.
Oct 26 2026 19:07:55
Hikal Management
| Name | Position |
|---|---|
| Rajasekhar Reddy | Company Secretary & Compliance Officer |
| Jai Hiremath | Chairman |
Hikal Similar Stocks
Solara Active Pharma Sciences Ltd.
640.60
-9.90 (1.52%)
Advanced Enzyme Technologies Ltd.
296.25
15.25 (5.43%)
Ind-Swift Laboratories Ltd.
331.00
-5.75 (1.71%)
Fredun Pharmaceuticals Ltd.
1707.00
70.60 (4.31%)
Sakar Healthcare Ltd.
976.20
-33.50 (3.32%)
Sai Parenteral's Ltd.
495.40
-6.35 (1.27%)
Panacea Biotec Ltd.
354.00
-2.55 (0.72%)
Hikal FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in HIKAL
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC